UniProt ID | THOC5_HUMAN | |
---|---|---|
UniProt AC | Q13769 | |
Protein Name | THO complex subunit 5 homolog | |
Gene Name | THOC5 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 683 | |
Subcellular Localization | Nucleus . Cytoplasm . Shuttles between nucleus and cytoplasm. | |
Protein Description | Acts as component of the THO subcomplex of the TREX complex which is thought to couple mRNA transcription, processing and nuclear export, and which specifically associates with spliced mRNA and not with unspliced pre-mRNA. TREX is recruited to spliced mRNAs by a transcription-independent mechanism, binds to mRNA upstream of the exon-junction complex (EJC) and is recruited in a splicing- and cap-dependent manner to a region near the 5' end of the mRNA where it functions in mRNA export to the cytoplasm via the TAP/NFX1 pathway. The TREX complex is essential for the export of Kaposi's sarcoma-associated herpesvirus (KSHV) intronless mRNAs and infectious virus production. THOC5 in conjunction with ALYREF/THOC4 functions in NXF1-NXT1 mediated nuclear export of HSP70 mRNA; both proteins enhance the RNA binding activity of NXF1 and are required for NXF1 localization to the nuclear rim. Involved in transcription elongation and genome stability. Involved in alternative polyadenylation site choice by recruiting CPSF6 to 5' region of target genes; probably mediates association of the TREX and CFIm complexes.; Regulates the expression of myeloid transcription factors CEBPA, CEBPB and GAB2 by enhancing the levels of phosphatidylinositol 3,4,5-trisphosphate. May be involved in the differentiation of granulocytes and adipocytes. Essential for hematopoietic primitive cell survival and plays an integral role in monocytic development.. | |
Protein Sequence | MSSESSKKRKPKVIRSDGAPAEGKRNRSDTEQEGKYYSEEAEVDLRDPGRDYELYKYTCQELQRLMAEIQDLKSRGGKDVAIEIEERRIQSCVHFMTLKKLNRLAHIRLKKGRDQTHEAKQKVDAYHLQLQNLLYEVMHLQKEITKCLEFKSKHEEIDLVSLEEFYKEAPPDISKAEVTMGDPHQQTLARLDWELEQRKRLAEKYRECLSNKEKILKEIEVKKEYLSSLQPRLNSIMQASLPVQEYLFMPFDQAHKQYETARHLPPPLYVLFVQATAYGQACDKTLSVAIEGSVDEAKALFKPPEDSQDDESDSDAEEEQTTKRRRPTLGVQLDDKRKEMLKRHPLSVMLDLKCKDDSVLHLTFYYLMNLNIMTVKAKVTTAMELITPISAGDLLSPDSVLSCLYPGDHGKKTPNPANQYQFDKVGILTLSDYVLELGHPYLWVQKLGGLHFPKEQPQQTVIADHSLSASHMETTMKLLKTRVQSRLALHKQFASLEHGIVPVTSDCQYLFPAKVVSRLVKWVTVAHEDYMELHFTKDIVDAGLAGDTNLYYMALIERGTAKLQAAVVLNPGYSSIPPVFQLCLNWKGEKTNSNDDNIRAMEGEVNVCYKELCGPWPSHQLLTNQLQRLCVLLDVYLETESHDDSVEGPKEFPQEKMCLRLFRGPSRMKPFKYNHPQGFFSHR | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Phosphorylation | ------MSSESSKKR ------CCCCHHHCC | 42.69 | 20068231 | |
2 | Acetylation | ------MSSESSKKR ------CCCCHHHCC | 42.69 | 22814378 | |
2 | O-linked_Glycosylation | ------MSSESSKKR ------CCCCHHHCC | 42.69 | 30379171 | |
3 | Phosphorylation | -----MSSESSKKRK -----CCCCHHHCCC | 39.95 | 20068231 | |
5 | Phosphorylation | ---MSSESSKKRKPK ---CCCCHHHCCCCC | 49.78 | 15221008 | |
6 | Phosphorylation | --MSSESSKKRKPKV --CCCCHHHCCCCCE | 37.84 | 15221008 | |
16 | Phosphorylation | RKPKVIRSDGAPAEG CCCCEECCCCCCCCC | 29.31 | 20068231 | |
24 | Acetylation | DGAPAEGKRNRSDTE CCCCCCCCCCCCCCH | 37.70 | 23954790 | |
28 | Phosphorylation | AEGKRNRSDTEQEGK CCCCCCCCCCHHCCC | 53.05 | 28176443 | |
30 | Phosphorylation | GKRNRSDTEQEGKYY CCCCCCCCHHCCCEE | 40.59 | 30576142 | |
37 | Phosphorylation | TEQEGKYYSEEAEVD CHHCCCEECCCEEEC | 17.06 | - | |
56 | Ubiquitination | GRDYELYKYTCQELQ CCCHHHHHHHHHHHH | 46.86 | - | |
66 | Sulfoxidation | CQELQRLMAEIQDLK HHHHHHHHHHHHHHH | 3.24 | 21406390 | |
73 | 2-Hydroxyisobutyrylation | MAEIQDLKSRGGKDV HHHHHHHHHCCCCCE | 46.53 | - | |
74 | O-linked_Glycosylation | AEIQDLKSRGGKDVA HHHHHHHHCCCCCEE | 43.38 | 30379171 | |
78 | Acetylation | DLKSRGGKDVAIEIE HHHHCCCCCEEEEEH | 52.43 | 26051181 | |
146 | Ubiquitination | HLQKEITKCLEFKSK HHHHHHHHHHHHHHC | 42.35 | - | |
153 | Sumoylation | KCLEFKSKHEEIDLV HHHHHHHCCCCCCEE | 56.47 | 28112733 | |
175 | Ubiquitination | EAPPDISKAEVTMGD HCCCCCCCCEECCCC | 49.23 | - | |
180 | Sulfoxidation | ISKAEVTMGDPHQQT CCCCEECCCCHHHHH | 7.47 | 21406390 | |
204 | Acetylation | QRKRLAEKYRECLSN HHHHHHHHHHHHHHC | 43.96 | 26051181 | |
210 | Phosphorylation | EKYRECLSNKEKILK HHHHHHHHCHHHHHH | 58.47 | - | |
212 | Acetylation | YRECLSNKEKILKEI HHHHHHCHHHHHHHH | 57.94 | 26051181 | |
217 | 2-Hydroxyisobutyrylation | SNKEKILKEIEVKKE HCHHHHHHHHHHHHH | 61.18 | - | |
217 | Acetylation | SNKEKILKEIEVKKE HCHHHHHHHHHHHHH | 61.18 | 26051181 | |
217 | Ubiquitination | SNKEKILKEIEVKKE HCHHHHHHHHHHHHH | 61.18 | - | |
222 | Ubiquitination | ILKEIEVKKEYLSSL HHHHHHHHHHHHHHC | 27.39 | - | |
223 | 2-Hydroxyisobutyrylation | LKEIEVKKEYLSSLQ HHHHHHHHHHHHHCH | 57.69 | - | |
223 | Ubiquitination | LKEIEVKKEYLSSLQ HHHHHHHHHHHHHCH | 57.69 | - | |
225 | Phosphorylation | EIEVKKEYLSSLQPR HHHHHHHHHHHCHHH | 22.29 | 18373705 | |
293 | Phosphorylation | LSVAIEGSVDEAKAL EEEEEECCHHHHHHH | 17.38 | - | |
307 | Phosphorylation | LFKPPEDSQDDESDS HCCCCCCCCCCCCCC | 33.57 | 26846344 | |
312 | Phosphorylation | EDSQDDESDSDAEEE CCCCCCCCCCHHHHH | 49.78 | 26846344 | |
314 | Phosphorylation | SQDDESDSDAEEEQT CCCCCCCCHHHHHHH | 48.26 | 26846344 | |
321 | Phosphorylation | SDAEEEQTTKRRRPT CHHHHHHHHHHCCCC | 37.25 | 23927012 | |
322 | Phosphorylation | DAEEEQTTKRRRPTL HHHHHHHHHHCCCCC | 23.42 | 23927012 | |
328 | Phosphorylation | TTKRRRPTLGVQLDD HHHHCCCCCCCCCCH | 34.04 | 29255136 | |
336 | Ubiquitination | LGVQLDDKRKEMLKR CCCCCCHHHHHHHHH | 66.10 | - | |
347 | Phosphorylation | MLKRHPLSVMLDLKC HHHHCCCEEEEEEEE | 15.21 | 20068231 | |
412 | Ubiquitination | YPGDHGKKTPNPANQ CCCCCCCCCCCCCCC | 74.03 | - | |
420 | Phosphorylation | TPNPANQYQFDKVGI CCCCCCCCCCCCEEE | 15.79 | - | |
477 | Ubiquitination | SHMETTMKLLKTRVQ HHHHHHHHHHHHHHH | 48.88 | - | |
477 | Acetylation | SHMETTMKLLKTRVQ HHHHHHHHHHHHHHH | 48.88 | 25953088 | |
491 | Acetylation | QSRLALHKQFASLEH HHHHHHHHHHHCCCC | 48.22 | 26051181 | |
514 | Ubiquitination | CQYLFPAKVVSRLVK CCEECCHHHHHHHHH | 43.33 | - | |
517 | Phosphorylation | LFPAKVVSRLVKWVT ECCHHHHHHHHHHHH | 23.92 | 27174698 | |
524 | Phosphorylation | SRLVKWVTVAHEDYM HHHHHHHHHCCHHHH | 15.74 | 27174698 | |
530 | Phosphorylation | VTVAHEDYMELHFTK HHHCCHHHHHHEECC | 6.90 | 27174698 | |
536 | Phosphorylation | DYMELHFTKDIVDAG HHHHHEECCCCHHCC | 19.63 | 27174698 | |
610 | Acetylation | GEVNVCYKELCGPWP CCEEEEHHHHHCCCC | 38.80 | 26051181 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
5 | S | Phosphorylation | Kinase | PRKCA | P17252 | GPS |
6 | S | Phosphorylation | Kinase | PRKCA | P17252 | GPS |
225 | Y | Phosphorylation | Kinase | PDGFRB | P09619 | PSP |
225 | Y | Phosphorylation | Kinase | SRC | P12931 | Uniprot |
307 | S | Phosphorylation | Kinase | ATM | Q13315 | PSP |
312 | S | Phosphorylation | Kinase | ATM | Q13315 | PSP |
314 | S | Phosphorylation | Kinase | ATM | Q13315 | PSP |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of THOC5_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307; SER-312 ANDSER-314, AND MASS SPECTROMETRY. | |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312 AND SER-314, ANDMASS SPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307; SER-312 ANDSER-314, AND MASS SPECTROMETRY. | |
"ATM and ATR substrate analysis reveals extensive protein networksresponsive to DNA damage."; Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.; Science 316:1160-1166(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307; SER-312 ANDSER-314, AND MASS SPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312 AND SER-314, ANDMASS SPECTROMETRY. | |
"THOC5 spliceosome protein: a target for leukaemogenic tyrosinekinases that affects inositol lipid turnover."; Pierce A., Carney L., Hamza H.G., Griffiths J.R., Zhang L.,Whetton B.A., Gonzalez Sanchez M.B., Tamura T., Sternberg D.,Whetton A.D.; Br. J. Haematol. 141:641-650(2008). Cited for: MASS SPECTROMETRY, AND PHOSPHORYLATION AT TYR-225. |